https://orcid.org/0000-0002-3869-2167
References
- Venneti S, Huse JT. The evolving molecular genetics of low-grade glioma. Adv Anat Pathol. 2015;22(2):94–101. doi:10.1097/pap.0000000000000049
- Ohgaki H, Kleihues P. The definition of primary and secondary glioblastoma. Clin Cancer Res. 2013;19(4):764–772. doi:10.1158/1078-0432.Ccr-12-3002
- Hai L, Zhang C, Li T, et al. Notch1 is a prognostic factor that is distinctly activated in the classical and proneural subtype of glioblastoma and that promotes glioma cell survival via the NF-κB(p65) pathway. Cell Death Dis. 2018;9(2):158. doi:10.1038/s41419-017-0119-z
- Tao Z, Li T, Ma H, et al. Autophagy suppresses self-renewal ability and tumorigenicity of glioma-initiating cells and promotes Notch1 degradation. Cell Death Dis. 2018;9(11):1063. doi:10.1038/s41419-018-0957-3
- Yi L, Zhou X, Li T, et al. Notch1 signaling pathway promotes invasion, self-renewal and growth of glioma initiating cells via modulating chemokine system CXCL12/CXCR4. J Exp Clin Cancer Res. 2019;38(1):339. doi:10.1186/s13046-019-1319-4
- Tong L, Li J, Li Q, et al. ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma. Theranostics. 2020;10(13):5943–5956. doi:10.7150/thno.41498
- Lim SO, Li CW, Xia W, et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell. 2016;30(6):925–939. doi:10.1016/j.ccell.2016.10.010
- Li Q, Sun Y, Liu B, et al. ACT001 modulates the NF-κB/MnSOD/ROS axis by targeting IKKβ to inhibit glioblastoma cell growth. J Mol Med. 2020;98(2):263–277. doi:10.1007/s00109-019-01839-0
- Kolmykov S, Yevshin I, Kulyashov M, et al. GTRD: an integrated view of transcription regulation. Nucleic Acids Res. 2021;49(D1):D104–D111. doi:10.1093/nar/gkaa1057
- Li Y, Xiao J, Bai J, et al. Molecular characterization and clinical relevance of m(6)A regulators across 33 cancer types. Mol Cancer. 2019;18(1):137. doi:10.1186/s12943-019-1066-3
- Mathur R, Zhang Y, Grimmer MR, et al. MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence. Neuro Oncol. 2020;22(11):1580–1590. doi:10.1093/neuonc/noaa059
- Bell EH, Zhang P, Fisher BJ, et al. Association of MGMT promoter methylation status with survival outcomes in patients with high-risk glioma treated with radiotherapy and temozolomide: an analysis from the NRG oncology/RTOG 0424 trial. JAMA Oncol. 2018;4(10):1405–1409. doi:10.1001/jamaoncol.2018.1977
- Vandeweyer G, Helsmoortel C, Van Dijck A, et al. The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism. Am J Med Genet C Semin Med Genet. 2014;166c(3):315–326. doi:10.1002/ajmg.c.31413
- Tekendo-Ngongang C, Kruszka P, Martinez AF, Muenke M. Novel heterozygous variants in KMT2D associated with holoprosencephaly. Clin Genet. 2019;96(3):266–270. doi:10.1111/cge.13598
- Froimchuk E, Jang Y, Ge K. Histone H3 lysine 4 methyltransferase KMT2D. Gene. 2017;627:337–342. doi:10.1016/j.gene.2017.06.056
- Gjorgjevski M, Hannen R, Carl B, et al. Molecular profiling of the tumor microenvironment in glioblastoma patients: correlation of microglia/macrophage polarization state with metalloprotease expression profiles and survival. Biosci Rep. 2019;39(6). doi:10.1042/bsr20182361
- Szulzewsky F, Pelz A, Feng X, et al. Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. PLoS One. 2015;10(2):e0116644. doi:10.1371/journal.pone.0116644
- Maleki Vareki S. High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018;6(1):157. doi:10.1186/s40425-018-0479-7